- Conditions
- Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, HR+/HER2- Ductal and Lobular Breast Cancer, Triple Negative Breast Cancer, Colorectal Cancer
- Interventions
- [68Ga]Ga-NNS309, [177Lu]Lu-NNS309
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 162 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2031
- U.S. locations
- 9
- States / cities
- Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 6 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 313–336
of 1,758
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Lupus Nephritis
- Interventions
- ianalumab s.c. q4w, ianalumab s.c. q12w, placebo s.c.
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 452 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2031
- U.S. locations
- 25
- States / cities
- Birmingham, Alabama • La Palma, California • Orange, California + 20 more
- Conditions
- In Escalation: All Patients With Solid Tumors and Lymphoma, In Expansion: Melanoma, Non-small Cell Lung Cancer
- Interventions
- NIZ985, Spartalizumab, Tislelizumab
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 2
- States / cities
- Duarte, California • La Jolla, California
- Conditions
- Sickle Cell Disease
- Interventions
- OTQ923
- Biological
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2039
- U.S. locations
- 3
- States / cities
- Chicago, Illinois • New York, New York • Memphis, Tennessee
- Conditions
- Rheumatoid Arthritis
- Interventions
- CFZ533, Placebo
- Biological · Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 75 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2017
- U.S. locations
- 5
- States / cities
- Anniston, Alabama • Miami, Florida • South Miami, Florida + 2 more
- Conditions
- Neurofibromatosis Type 2, Neuroma, Acoustic
- Interventions
- RAD001, everolimus
- Drug
- Lead sponsor
- Jonsson Comprehensive Cancer Center
- Other
- Eligibility
- 16 Years to 65 Years
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2024
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- ASA404, Placebo, docetaxel
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 900 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2008
- U.S. locations
- 88
- States / cities
- Huntsville, Alabama • Tucson, Arizona • Bentonville, Arkansas + 76 more
- Conditions
- Asthma
- Interventions
- Omalizumab
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 6 Years to 11 Years
- Enrollment
- 16,246 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020
- U.S. locations
- 1
- States / cities
- East Hanover, New Jersey
- Conditions
- Acute Myeloid Leukemia
- Interventions
- Midostaurin, Cytarabine
- Drug
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 18 Years to 75 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 1
- States / cities
- Gainesville, Florida
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- VAY736, Placebo, Standard of Care (SoC)
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 40 Years to 80 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 7
- States / cities
- Birmingham, Alabama • Aurora, Colorado • Miami, Florida + 4 more
- Conditions
- Hepatic Impairment
- Interventions
- Siremadlin
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 38 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 3
- States / cities
- Miami, Florida • Orlando, Florida • San Antonio, Texas
- Conditions
- Diffuse Large B-Cell Lymphoma (DLBCL), Acute Lymphoblastic Leukemia (ALL)
- Interventions
- KYMRIAH, YESCARTA
- Other
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 30 Years
- Enrollment
- 273 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- East Hanover, New Jersey
- Conditions
- Normal Hepatic Function, Impaired Hepatic Function
- Interventions
- LDK378
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2016
- U.S. locations
- 5
- States / cities
- Lakewood, Colorado • DeLand, Florida • Miami, Florida + 2 more
- Conditions
- Acromegaly
- Interventions
- Pasireotide long acting release formulation
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 37
- States / cities
- Birmingham, Alabama • Peoria, Arizona • Phoenix, Arizona + 30 more
- Conditions
- Prostate Cancer
- Interventions
- zoledronic acid
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older · Male only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2007
- U.S. locations
- 16
- States / cities
- Tucson, Arizona • Long Beach, California • Washington D.C., District of Columbia + 13 more
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- QVA149, Umeclidinium/vilanterol, Placebo (umeclidinium/vilanterol ), Placebo (QVA149)
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 355 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 53
- States / cities
- Anaheim, California • Escondido, California • Riverside, California + 45 more
- Conditions
- BRAF-positive Metastatic Melanoma
- Interventions
- Not listed
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 785 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022
- U.S. locations
- 1
- States / cities
- East Hanover, New Jersey
- Conditions
- Chronic Hepatitis B
- Interventions
- Telbivudine (LdT)
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 16 Years to 70 Years
- Enrollment
- 1,869 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2009
- U.S. locations
- 19
- States / cities
- Phoenix, Arizona • Los Angeles, California • Pasadena, California + 15 more
- Conditions
- Small Cell Lung Carcinoma, Large Cell Neuroendocrine Carcinoma of the Lung, Neuroendocrine Prostate Cancer, Gastroenteropancreatic Neuroendocrine Carcinoma, Non-prostate Extrapulmonary Neuroendocrine Carcinoma, Cervical Neuroendocrine Carcinoma, Thymic Neuroendocrine Carcinoma, Genitourinary Neuroendocrine Carcinoma, Unknown Primary Neuroendocrine Carcinomas, Merkel Cell Carcinoma, Medullary Thyroid Carcinoma
- Interventions
- 225Ac-ETN029, 111In-ETN029
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 116 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2031
- U.S. locations
- 4
- States / cities
- Iowa City, Iowa • Boston, Massachusetts • Royal Oak, Michigan + 1 more
- Conditions
- Arthritis, Psoriatic
- Interventions
- Secukinumab, Placebo
- Biological · Other
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 341 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 19
- States / cities
- Mesa, Arizona • Upland, California • Denver, Colorado + 15 more
- Conditions
- Hematologic Malignancy, Solid Tumor, Advanced Malignancies
- Interventions
- Pelabresib
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 6
- States / cities
- Los Angeles, California • Jacksonville, Florida • Chicago, Illinois + 2 more
- Conditions
- Hepatic Failure
- Interventions
- Icenticaftor
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2022
- U.S. locations
- 2
- States / cities
- Miami, Florida • Orlando, Florida
- Conditions
- Atherosclerosis
- Interventions
- Canakinumab, Placebo, Standard of care
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 10,066 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2019
- U.S. locations
- 315
- States / cities
- Athens, Alabama • Birmingham, Alabama • Fairhope, Alabama + 248 more
- Conditions
- Pulmonary Sarcoidosis
- Interventions
- ACZ885, Placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 3
- States / cities
- Birmingham, Alabama • Albany, New York • Cleveland, Ohio